[{"Assets_0_Q2_USD":1138891000.0,"CommonStockSharesOutstanding_0_Q2_shares":50014528.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":33591000.0,"NetIncomeLoss_1_Q2_USD":50144000.0,"NetIncomeLoss_2_Q2_USD":45236000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":51162909.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":51039195.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":49896124.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":49738980.0,"EarningsPerShareBasic_1_Q2_USD":1.0,"EarningsPerShareBasic_2_Q2_USD":0.91,"EarningsPerShareDiluted_1_Q2_USD":0.98,"EarningsPerShareDiluted_2_Q2_USD":0.89,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":220200000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":338014000.0,"Ticker":"EBS","CIK":"1367644","name":"EMERGENT BIOSOLUTIONS INC.","OfficialName":"Emergent Biosolutions Inc. Common Stock","form":"10-Q","period":"20180630","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"2077670312.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NYSE","SP500":"nan","filed":"20180803"}]